$AVBP 8-K/A SEC Filings

Filed On	Filing
09 Jul 2024	8-K/A: Departure/Election of Directors or Officers; Compensation NEWTON SQUARE, PA – April 22, 2024 – ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson t...
09 Jul 2024	8-K/A: Departure/Election of Directors or Officers; Compensation As previously reported on the Current Report on Form 8-K (the “Original Filing”) filed by ArriVent BioPharma, Inc. (the “Company”) on May 16, 2024, the Company’s Board of Directors (the “Board”) appointed John Hohneker, M.D. as a new dir...